Burden of antimicrobial resistance in an era of decreasing susceptibility

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 7, 2017, Pages 663-676

  Tillotson, Glenn S ^a   Zinner, Stephen H ^b  

^a GST Micro LLC   (United States)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Antimicrobial resistance; economic costs; length of hospital stay; mortality

Indexed keywords

ANTIBIOTIC RESISTANCE; CLINICAL OUTCOME; ESCHERICHIA COLI; HOSPITALIZATION; HUMAN; INTERNET; KLEBSIELLA PNEUMONIAE; MEDLINE; MORTALITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; SCOPUS; SEARCH ENGINE; SPECIES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; BACTERIAL INFECTION; ECONOMICS; HEALTH CARE COST; MICROBIOLOGY; PATHOLOGY; TRENDS;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS;

EID: 85022058157     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1337508     Document Type: Review

References (62)

1. World Health Day:Media Fact Sheet, Antimicrobial resistance:no action today, no cure tomorrow. Centers for Disease Control and Prevention; 2011. Available from:http://www.cdc.gove/media
2. Antibiotic Resistance:Multi-country Public Awareness Survey. World Health Organization; 2015. Available from:http://www.who.int/drugresistance/documents/baselinesurveynov2015/en/
3. Antibiotic Resistance Threats in the United States 2013. Centers for Disease Control and Prevention; 2013. Available from:https://www.cdc.gov/drugresistance/threat-report-2013/index.html
4. 2015 Summary report on antimicrobials sold or distributed for use in food-producing animals. FDA, Center for Veterinary Medicine; 2015. Available from:http://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm534244.htm
5. Additives for use in animal nutrition. European Parliament and the Council of the European Union; 2003. Available from:http://data.europa.eu/eli/reg/2003/1831/oj
6. Fair RJ, Tor Y., Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem. 2014;6:25–64.
7. Antimicrobial resistance:global report on surveillance 2014. World Health Organization; 2014 [cited 2014 Apr]. Available from:http://www.who.int/drugresistance/documents/surveillancereport/en/
8. Fischbach MA, Walsh CT., Antibiotics for emerging pathogens. Science (New York, NY). 2009;325:1089–1093. Epub 2009/08/29.
9. Antimicrobial Resistance:Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance; 2014. Available from:https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
10. Taylor J, Hafner M, Yerushalmi E, et al. Estimating the economic costs of antimicrobial resistance:Model and Results. RAND Corporation; 2014.
11. Selfin Y, The global economic impact of antimicrobial resistance. KPMG UK; 2014. Available from:https://home.kpmg.com/content/dam/kpmg/pdf/2014/12/amr-report-final.pdf
12. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections:summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–1301. Epub 2016/10/22.
13. Antimicrobial Surveillance in Europe 2014. European Centre for Disease Prevention and Control; 2014. Available from:http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf
14. Micek S, Johnson MT, Reichley R, et al. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis. 2012;12:56. Epub 2012/03/15.•• A real-world example of the direct impact of antibiotic use in sepsis, a growing clinical problem.
15. Hu B, Ye H, Xu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin. 2010;26:1443–1449.
16. Mauldin PD, Salgado CD, Hansen IS, et al. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54:109–115. Epub 2009/10/21.
17. Chandy SJ, Naik GS, Balaji V, et al. High cost burden and health consequences of antibiotic resistance:the price to pay. J Infect Dev Ctries. 2014;8:1096–1102.
18. Alam MF, Cohen D, Butler C, et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents. 2009;33:255–257. Epub 2008/12/19.
19. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–4091.
20. Riu M, Chiarello P, Terradas R, et al. Cost attributable to nosocomial bacteremia. Analysis according to microorganism and antimicrobial sensitivity in a University Hospital in Barcelona. PLoS One. 2016;11:e0153076.• The specificity of organisms and antibiotic resistance has rarely been reported, especially from one institution.
21. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, et al. Impact of antimicrobial multidrug resistance on inpatient care cost:an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013;11:321–331. Epub 2013/03/06.
22. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago Teaching Hospital:implications for antibiotic stewardship. Clin Infect Dis Off Publ Infect Dis Soc America. 2009;49:1175–1184. Epub 2009/09/11.
23. Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2017;23:48.e9-.e16. Epub 2016/10/30.•• CRE are increasing in incidence in many countries; this study highlights the vast array of costs which can be affected by inappropriate antibiotic therapy. It provides a basis for other countries to calculate their own economic implications of this emerging issue.
24. Lagace-Wiens PR, Adam HJ, Low DE, et al. Canadian Antimicrobial Resistance A. Trends in antibiotic resistance over time among pathogens from Canadian hospitals:results of the CANWARD study 2007-11. J Antimicrob Chemother. 2013;68(Suppl 1):i23–9.
25. Pakyz AL, Lee JA, Ababneh MA, et al. Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitals. J Antimicrob Chemother. 2012;67:1562–1564.
26. Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22(Suppl 1):S9–S14.
27. Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections:mono or combination antimicrobial therapy? Curr Med Chem. 2008;15:517–522. Epub 2008/02/22.
28. Liu Q, Li X, Li W, et al. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection:a meta-analysis. Sci Rep. 2015;5:11715.
29. Kim YJ, Jun YH, Kim YR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC Infect Dis. 2014;14:161. Epub 2014/03/25.
30. Neidell MJ, Cohen B, Furuya Y, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis Off Publ Infect Dis Soc America. 2012;55:807–815. Epub 2012/06/16.
31. Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122. Epub 2012/05/25.
32. Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa:emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010;31:47–53.
33. Trends by Serotype Group. Centers for Disease Control and Prevention; 1998–2015. Available from:https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html
34. Ross JI, Eady EA, Cove JH, et al. 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998;42:1702–1705. Epub 1998/07/14.
35. Pneumonia Fact Sheet. World Health Organization; 2016. Available from:http://www.who.int/mediacentre/factsheets/fs331/en/
36. Flamm RKRP, Huband MD, Farrell DJ. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program. ICAAC, C–554; 2014–2015. Available from:http://paratekpharma.com/media/1056/flamm2015icaacactivity-against-str-pneumoniae.pdf
37. Keedy KLJ, Nenninger A, Sheets A, et al. Antibiotic susceptibility of Streptococcus pneumoniae in the USA in 2014. New Orleans:ID Week Conference 2016. 2016.
38. Surveillance of invasive bacterial diseases in Europe 2012. European Center for Disease Prevention and Control; 2012. Available from:http://ecdc.europa.eu/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf
39. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis Off Publ Infect Dis Soc America. 2007;44(Suppl 2):S27–72. Epub 2007/02/06.
40. Klepser ME, Klepser DG, Ernst EJ, et al. Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy. 2003;23:349–359. Epub 2003/03/12.
41. Einarsson S, Kristjansson M, Kristinsson KG, et al. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults:a case-control study. Scand J Infect Dis. 1998;30:253–256. Epub 1998/10/28.
42. Asche C, McAdam-Marx C, Seal B, et al. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008;61:1162–1168.•• This study uses real-world data in terms of failure of initial antibiotic therapy and the related costs of requiring further therapy. Macrolide therapy is highlighted a particular issue when using the threshold of 25% resistance as a clear factor in management of this common community infection.
43. McLaughlin JM, Johnson MH, Kagan SA, et al. Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011:a retrospective cohort study. Infection. 2015;43:671–680.
44. Ostermann H, Garau J, Medina J, et al. Resource use by patients hospitalized with community-acquired pneumonia in Europe:analysis of the REACH study. BMC Pulm Med. 2014;14:36. Epub 2014/03/07.
45. Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia. Plos One. 2013;8:e71375.
46. Baldo V, Cocchio S, Baldovin T, et al. A population-based study on the impact of hospitalization for pneumonia in different age groups. BMC Infect Dis. 2014;14:485. Epub 2014/09/07.
47. Reynolds CA, Finkelstein JA, Ray GT, et al. Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia:a cost analysis. Antimicrob Resist Infect Control. 2014;3:16. Epub 2014/05/23.
48. ABCs Report:Methicillin-resistant Staphylococcus aureus 2014. Centers for Disease Control and Prevention; 2014. Available from:https://www.cdc.gov/abcs/reports-findings/survreports/mrsa14.html
49. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance:a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–318. Epub 2015/09/08.
50. Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents. 2006;28:379–384. Epub 2006/10/19.
51. Gould IM, Reilly J, Bunyan D, et al. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2010;16:1721–1728. Epub 2010/09/10.
52. Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance:how much do we really know? Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20:973–980. Epub 2014/10/03.• This seminal paper highlights not only what we know of resistance and economic impact but also what we do not know and include in our maths.
53. Antonanzas F, Lozano C, Torres C. Economic features of antibiotic resistance:the case of methicillin-resistant Staphylococcus aureus. Pharmacoeconomics. 2015;33:285–325.• Although MRSA incidence is declining in Europe, in other countries it is still a major clinical challenge and is frequently not accounted for in initial empiric therapy. Traditional agents lacking activity against MRSA are still used and lead to clinical failure and unnecessary expense.
54. Rubio-Terres C, Garau J, Grau S, et al. Cast of Resistance Study g. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain:a retrospective cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2010;16:722–728.
55. De Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia:estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8:e1001104. Epub 2011/10/25.
56. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31:365–373.
57. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. Aureus Bloodstream Infection? Infect Control Hosp Epidemiol. 2009;30:453–460.
58. Ott E, Bange FC, Reichardt C, et al. Costs of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2010;76:300–303.
59. Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48:3258–3262.
60. Taneja C, Haque N, Oster G, et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med. 2010;5:528–534.
61. Parvizi J, Pawasarat IM, Azzam KA, et al. Periprosthetic joint infection:the economic impact of methicillin-resistant infections. J Arthroplasty. 2010;25:103–107.
62. Chen L, Todd R, Kiehlbauch J, et al. Notes from the field:pan-resistant New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae–Washoe County, Nevada, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:33. Epub 2017/01/13.